Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer

On November 18, 2026 Summit Therapeutics Inc. (NASDAQ: SMMT) reported the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF bispecific antibody, in non-small cell lung cancer (NSCLC). The study, HARMONi-10, will evaluate ivonescimab compared with durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. Consolidation therapy, given after a patient has responded to initial treatment, aims to deepen or prolong that response and delay or prevent the cancer from coming back or progressing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HARMONi-10 is Summit’s sixth sponsored Phase III study of ivonescimab and its fourth in NSCLC, following HARMONi, HARMONi-3, and HARMONi-7. The study extends Summit’s global clinical development program into the locally advanced, unresectable setting, where durvalumab, following curative-intent chemoradiation, is a current standard of care.

"HARMONi-10 is the next bold step in a clinical development program built to change what is possible for people with lung cancer," said Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit. "We are taking ivonescimab head-to-head against standard-of-care PD-L1 therapy in this global Phase III trial, in earlier stage disease, because we believe in its potential and intend to prove it. This is the rigor, ambition, and conviction we have brought to this program from day one."

HARMONi-10 is a multi-regional, open-label, potentially registration-enabling Phase III clinical trial. The primary endpoint of the study is progression-free survival (PFS). Global clinical trial site activations for HARMONi-10 are expected to begin in the fourth quarter of 2026.

"Patients with unresectable Stage III non-small cell lung cancer endure an intensive course of chemoradiation, and too often their disease still progresses thereafter despite current consolidation therapy," said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit. "In this curative-intent setting, this is a gap we are determined to close. With PD-1 and VEGF blockade in a single molecule, we believe ivonescimab has the potential to keep the disease from progressing for longer than durvalumab in this setting. We are moving with urgency to activate sites globally and bring ivonescimab to many more people living with lung cancer."

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.

This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab’s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.

Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally, and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.

There are currently 18 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, six of which are Summit-sponsored global studies, two of which are studies sponsored by cooperative groups, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC (HARMONi, HARMONi-3, HARMONi-7) and expanded its sponsored Phase III clinical development program into colorectal cancer (CRC; HARMONi-GI3) and urothelial carcinoma (bladder cancer; HARMONi-GU1). The two cooperative studies are in head and neck squamous cell carcinoma (HNSCC; ILLUMINE) and biliary tract cancer (BTC; EA2251). Summit announced the initiation of an additional Phase III trial in NSCLC, HARMONi-10, in November 2026.

HARMONi is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR TKI (e.g., osimertinib).

HARMONi-3 is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous or non-squamous NSCLC, irrespective of PD-L1 expression. The clinical trial is evaluating the two histologies as individual, separately powered cohorts with independent statistical powering.

HARMONi-7 is a Phase III clinical trial evaluating ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

HARMONi-10 is a Phase III clinical trial evaluating ivonescimab compared to durvalumab as consolidation therapy in patients with locally advanced, unresectable Stage III NSCLC who have not experienced disease progression following platinum-based concurrent chemoradiation therapy.

Five Phase III ivonescimab clinical trials have read out to date, all five with positive data. Four of these five studies are in NSCLC and one is in BTC. In addition to Summit’s positive HARMONi study in NSCLC, Akeso has had positive read-outs in four single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, HARMONi-6 (each in NSCLC), and HARMONi-GI1 (in BTC) for ivonescimab, including a statistically significant overall survival benefit in all four studies from China.

Akeso is actively conducting multiple Phase III clinical studies in settings outside of NSCLC and biliary-tract cancer, including triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

(Press release, Summit Therapeutics, NOV 18, 2026, View Source [SID1234674935])

Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045

On November 18, 2026 Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor, reported that the United States Patent and Trademark Office ("USPTO") has granted a U.S. patent covering stenoparib treatment regimens. The patent is to provide protection for the claimed methods into 2045.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 36 allowed claims cover twice-daily oral administration of stenoparib, including specified dose levels and treatment schedules relevant to Allarity’s clinical development program. They also encompass methods of treating advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic and prostate cancers, as well as patients whose disease has not responded to prior therapies, including other PARP inhibitors.

"The commercial significance of this patent is enormous. Its coverage of our twice-daily dosing strategy is critical as this is the dosing regimen we intend to advance to pivotal trials," said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. "A protection period extending into 2045 strengthens the foundation for continued investment in stenoparib and fuels future partnering discussions as we generate the clinical data needed to support FDA approval".

The patent complements Allarity’s previously issued U.S. patent covering its stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. Together, these patents enable the Company’s strategy to develop stenoparib alongside a proprietary approach to identifying patients most likely to benefit.

The patent, titled Methods for Treating Cancer, has been assigned U.S. Patent No. 12,806,205 and arises from U.S. Patent Application No. 18/606,590.

(Press release, Allarity Therapeutics, NOV 18, 2026, View Source [SID1234674920])

Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

On November 18, 2026 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or the "Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, reported new data from the investigator-initiated EFTISARC-NEO Phase II study presented at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting (Poster number P 448).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study is evaluating Immutep’s eftilagimod alfa (efti) in combination with KEYTRUDA (pembrolizumab) and radiotherapy before surgery in patients with high-risk, resectable soft tissue sarcoma. Forty patients were enrolled, and 38 patients underwent surgery and were included in the survival evaluation.

The latest analysis currently shows a disease-free survival (DFS) of 81.1% at 12 months. The current Kaplan-Meier estimate at 18 months is also 81.1%, although this later time point remains immature, and follow-up is ongoing. Among the 38 patients who underwent surgery and were evaluated, eight patients had experienced disease recurrence at the data cut-off (April 30, 2026).

Table 1 – Survival results for soft tissue sarcoma patients from EFTISARC-NEO

Outcome Latest Analysis
12-month disease-free survival (mature) 81.1%
18-month disease-free survival (immature) 81.1%
12-month local recurrence-free survival 94.1%
12-month distant metastasis-free survival 86.2%
Median follow-up 19.1 months

In addition, exploratory analyses showed that higher levels of tumour-infiltrating lymphocytes (TILs) and greater hyalinisation and fibrosis after treatment may be associated with better DFS. In particular, patients with post-treatment TIL levels above 310 cells/mm² had 95.0% 12-month DFS compared with 64.9% in patients with lower TIL levels. Patients with treatment-related hyalinisation and fibrosis greater than 52% had 93.8% 12-month DFS compared with 71.4% in patients with lower levels of hyalinisation and fibrosis. The presence of tertiary lymphoid structures (TLS) and baseline expression of PD-L1, LAG-3 and TIGIT did not correlate with survival outcomes.

These survival and exploratory findings build on previously reported EFTISARC-NEO results in which the trial met its primary endpoint with a median tumour hyalinisation/fibrosis of 51.5% following neoadjuvant therapy with efti, pembrolizumab and radiotherapy. The new data are consistent with efti’s mechanism of action, in which activation of antigen-presenting cells drives a stronger anti-tumour T cell response, and suggest that a stronger immune response in the tumour may be associated with improved patient survival outcomes.

Pawel Sobczuk, MD PhD, one of the Principal Investigators of EFTISARC-NEO, said: "These results are highly encouraging for patients with high-risk soft tissue sarcoma, where recurrence remains a major concern despite surgery and radiotherapy. Disease-free survival of approximately 81% maintained through 12 months and on a preliminary basis also at 18 months is an important observation, and the association between a strong immune response in the tumour and better disease-free survival is particularly compelling. Together with the substantial pathological responses previously reported, the findings reinforce the potential of this novel neoadjuvant approach and provide a strong rationale for continued follow-up and further clinical evaluation."

Marc Voigt, CEO of Immutep, said: "With the data to date, EFTISARC-NEO is delivering an increasingly coherent and encouraging picture. The marked difference in outcomes between patients with higher and lower post-treatment immune cell infiltration is especially notable and is consistent with efti’s potential to help generate a stronger anti-tumour immune response. We believe these results strengthen the rationale for further potential clinical development in this indication, where patients remain in need of more effective treatment options."

The poster is available on the Posters & Publications page of Immutep’s website.

Next Steps

Immutep anticipates reporting additional data from EFTISARC-NEO in CY2027.

Subject to regulatory interactions, manufacturing timelines, partnering arrangements and available resources, the Company is preparing to advance efti into a registration-directed clinical trial in neoadjuvant soft tissue sarcoma, targeting initiation in H2 CY2027.

About EFTISARC-NEO

EFTISARC-NEO is an investigator-initiated, open-label Phase II trial evaluating eftilagimod alfa (efti) in combination with KEYTRUDA (pembrolizumab) and radiotherapy as neoadjuvant treatment for patients with resectable soft tissue sarcoma. The trial is led by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and is primarily funded by a grant from the Polish Medical Research Agency, with Immutep supplying efti.

The primary endpoint is pathological response, measured as the percentage of tumour hyalinisation/fibrosis at resection. Secondary endpoints include safety, disease-free survival, local recurrence-free survival, distant metastasis-free survival, overall survival, radiological response and health-related quality of life. Forty patients were enrolled, with enrolment completed in January 2025 (ClinicalTrials.gov: NCT06128863).

About Eftilagimod Alfa (efti)

Eftilagimod alfa (efti) is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that activates antigen-presenting cells through the MHC Class II pathway, engaging both innate and adaptive immunity, including the priming of cytotoxic CD8+ T cells and the production of co-stimulatory signals and cytokines. Its favourable safety profile enables combination with anti-PD-(L)1 therapy, radiotherapy and/or chemotherapy. Efti has received Fast Track designation from the U.S. Food and Drug Administration in first-line head and neck squamous cell carcinoma and first-line non-small cell lung cancer, and Orphan Drug Designation in soft tissue sarcoma.

(Press release, Immutep, NOV 18, 2026, View Source [SID1234674936])

Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer

On November 18, 2026 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, reported that a late-breaking abstract featuring updated clinical data from the Phase 1/2 TARGET-D-101 study of VS-7375 in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer (NSCLC) has been selected for oral presentation at the IASLC/ASCO 2026 North America Conference on Lung Cancer (NACLC26), taking place December 4–6, 2026. A trial in progress (TiP) abstract on the Phase 2 TARGET-D 202 registration-directed NSCLC trial has also been accepted for poster presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For people with KRAS G12D-mutated lung cancer, the need for targeted treatment options remains significant. No therapy specifically targeting KRAS G12D is approved, and published research has associated this mutation with worse outcomes, including lower response rates and shorter progression-free survival than other common KRAS variants in metastatic NSCLC," said Michael G. Kauffman, M.D., Ph.D., President of Development at Verastem Oncology. "We’re advancing VS-7375, an investigational oral, selective KRAS G12D (ON/OFF) inhibitor with best-in-class potential to enable maximal antitumor efficacy with a favorable tolerability profile. The updated TARGET-D 101 data to be presented at the conference build on the findings we reported in October — including confirmed responses in previously treated NSCLC, with responses observed in patients who had received taxanes. Together, these findings support our broader strategy to move VS-7375 toward the frontline setting."

Late-Breaking Oral Presentation
Title: Preliminary Efficacy and Safety of VS-7375 in Previously Treated KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer: Results From the Phase 1/2 TARGET-D-101 Study
Date and time: Saturday, December 5, 2026, 2:45-4:15 p.m. MST
Presenter: Marcelo V. Negrao, M.D., Department of Thoracic-Head & Neck Med Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center
Abstract Session: Oral Abstract Session 1 (OA01)

TiP Poster Presentation
Title: TARGET-D 202: A Phase 2 Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer
Date and time: Saturday, December 5, 2026, 4:15-5:45 p.m. MST
Presenter: Matthew Gumbleton, M.D., Ph.D., Assistant Professor at the University of Utah, Huntsman Cancer Institute
Poster Session: Poster Viewing Reception (PP01.119)

About KRAS G12D
KRAS G12D represents 26% of all KRAS mutations, making it the most prevalent KRAS mutation in human cancers. When the KRAS gene is mutated, it can promote cancer development and growth. Patients with KRAS G12D-mutant tumors often have poorer outcomes, underscoring the need for therapies designed specifically to inhibit this mutation potently and for a long duration. The KRAS G12D mutation occurs most commonly in pancreatic (40%), colorectal (15%), and non-small cell lung (5%) cancers. Currently, no therapies are approved by the U.S. Food and Drug Administration (FDA) specifically targeting KRAS G12D mutations in cancer.

About VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor & TARGET-D Clinical Program
VS-7375 is a potential best-in-class, potent, and selective investigational oral KRAS G12D dual ON/OFF inhibitor. It is designed to uniquely bind to both the active (ON) and inactive (OFF) states of KRAS G12D, with the potential to inhibit KRAS G12D signaling and tumor growth more completely than compounds that block KRAS G12D only in the OFF state or only in the ON state.

In June 2025, Verastem initiated TARGET-D 101, a Phase 1/2 dose escalation, dose expansion, and combination clinical trial evaluating the safety and efficacy of VS-7375 in patients with advanced KRAS G12D mutant solid tumors. Verastem has further expanded the VS-7375 clinical program with the initiation of three Phase 2 registration-directed, open-label clinical trials that are enrolling patients: TARGET-D 201 (NCT07644559) in metastatic pancreatic ductal carcinoma, TARGET-D 202 (NCT07659782) in advanced non-small cell lung cancer, and TARGET-D 203 (NCT07659795) in metastatic colorectal cancer.

In July 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to VS-7375 for the first-line treatment of patients with KRAS G12D-mutated locally advanced or metastatic adenocarcinoma of the pancreas and for the treatment of patients with KRAS G12D-mutated locally advanced or metastatic pancreatic ductal carcinoma who have received at least one prior line of standard systemic therapy. In June 2026, the FDA also granted FTD to VS-7375 for the treatment of adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody either concurrently or sequentially.

In January 2025, Verastem exercised its license for VS-7375 from GenFleet Therapeutics. The license gives Verastem development and commercialization rights outside the GenFleet markets of mainland China, Hong Kong, Macau, and Taiwan. GenFleet is developing VS-7375 as GFH375 in China.

(Press release, Verastem, NOV 18, 2026, View Source [SID1234674921])

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium

On November 18, 2026 Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, reported updated results from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The results will be presented on November 19, 2026, by Faye Johnson, M.D., Ph.D., professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, in a late-breaking oral presentation at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

The updated data, as of October 14, 2026, demonstrated a 39% confirmed objective response rate (cORR), 94% disease control rate (DCR), median progression-free survival (mPFS) of 6.7 months, 12-month overall survival (OS) probability of 81%, and newly reported median duration of response (mDOR) of 9.2 months among 33 efficacy evaluable patients dosed at 5.4 mg/kg intravenously once every three weeks with a dose equivalent to or below a dose cap. Together, these results provide further evidence of clinical activity across HPV statuses and prior-treatment subgroups, with an expected and manageable tolerability profile.

"We are grateful to the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium for highlighting these updated MICVO data in 2L+ R/M HNSCC, and to Dr. Johnson for presenting these important new results," said Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology. "The data from October show improvements across multiple key clinical activity endpoints with a novel analysis showing that MICVO increased mPFS by 50% versus the most recent prior therapy patients had received before MICVO. We are also very happy to report that our clinical strategy for managing safety has had the intended impact. There have been no new cases of Grade 3 peripheral neuropathy and the six patients that experienced Grade 3 peripheral neuropathy have all improved with five of the six patients resolving to Grade 1 or better. Collectively, this updated data profile, and the new analyses further support our plan to advance MICVO into the global Phase 3 HeadlinerSM trial in 2L+ R/M HNSCC, which we expect to initiate in mid-2027. With important regulatory meetings in the near term and more mature overall survival (OS) data expected in the first half of 2027, we remain confident in our path forward."

"For patients whose disease progresses after platinum chemotherapy and immunotherapy, there remains a substantial unmet medical need, particularly as we anticipate broader use of EGFR-targeted therapies in earlier lines of treatment," said Dr. Johnson. "It is reassuring to see responses that last in this setting and, if confirmed in a larger study, MICVO could potentially offer these patients a meaningful new treatment option."

Updated MICVO Phase 1 Monotherapy Trial Results as of October 14, 2026

Table 1: Survival and Durability

Categories October 2026
Median progression-free survival (mPFS), months 6.7
12-month overall survival (OS) probability, % 81%
Median duration of response (mDOR), months 9.2
Data as of 14-Oct-2026

Table 2: Responses

Categories Groups (N) October 2026
Overall cORR (N=33) 39%
c+uORR (N=33) 52%
DCR (N=33) 94%
HPV Status cORR HPV+ (N=17) 41%
cORR HPV-Unrelated (N=16) 38%
Prior EGFRi cORR Prior EGFRi (N=18) 33%
cORR Prior Novel EGFRi (N=5) 60%
cORR No EGFRi (N=15) 47%
Line of Therapy cORR 2L (N=11) 46%
cORR 3L (N=20) 40%
Prior Taxane cORR Prior Taxane (N=23) 39%
cORR No Taxane (N=10) 40%
Data as of 14-Oct-2026; c+uORR: 4 patients with uPR include: N=2 patients had PD on subsequent scan, N=1 lost to follow-up, and N=1 had 3 subsequent tumor assessments as not evaluable and the following scan as PD due to growth of a non-target lesion 216 days after first dose.
Abbreviations: 2L: second-line; 3L: third-line; cORR: confirmed objective response rate; c+uORR: confirmed plus unconfirmed objective response rate; DCR: disease control rate; HPV: human papillomavirus; EGFRi: EGFR inhibitor; n/N: number of patients; uPR: unconfirmed partial response

Table 3: Incremental Analysis from August 18, 2026 Data

Categories Groups (N) October 2026
Resolution of Grade 3 Peripheral Neuropathy Grade 3 Peripheral Neuropathy (N=6) Resolving to Grade 1 or better 83%
Grade 3 Peripheral Neuropathy (N=6) Resolving to Grade 2 17%
Grade 3 Peripheral Neuropathy (N=6) Not Resolving 0%
Peripheral Neuropathy and prior taxane use Any Grade Peripheral Neuropathy for patients with (N=25) or without (N=11) prior taxane Prior Taxane: 68%
No Prior Taxane: 36%
Grade 3 Peripheral Neuropathy for patients with (N=25) or without (N=11) prior taxane Prior Taxane: 20%
No Prior Taxane: 9%
Impact of dose cap for males above 80kg and females above 70kg cORR dosed above cap (N=9) vs. patients receiving capped dose (N=5) Dosed above cap: 44%
Capped dose: 60%
TRAEs leading to discontinuation dosed above cap (N=9) vs. patients receiving capped dose (N=5) Dosed above cap d/c: 56%
Capped dose d/c: 20%
Grade 3 Treatment-Related Peripheral Neuropathy dosed above cap (N=9) vs. patients receiving capped dose (N=5) Dosed above cap Gr3 PN: 67%
Capped dose Gr3 PN: 0%
PFS on MICVO vs. Prior Therapy mPFS on most recent prior therapy (N=33), months (95% CI) 4.2 (2.8-5.6)
mPFS on MICVO (N=33), months (95% CI) 6.7 (4.8-9.0)
Data as of 14-Oct-2026
Abbreviations: cORR: confirmed objective response rate; d/c: discontinue; TRAE: treatment-related adverse event; Gr: grade; MICVO: micvotabart pelidotin; mPFS: median progression-free survival; N: number of patients; PN: Peripheral Neuropathy; CI: confidence interval.

Late-Breaking Oral Presentation Details
Title: Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Faye Johnson, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
Session: Proffered Papers: Clinical Trials
Abstract number: 3LBA
Date and time: Thursday, November 19, 2026, 10:00 – 11:30 CET
Location: Room 111 + 112

Live Webcast
Pyxis Oncology will host a live webcast on Thursday, November 19, 2026, at 7:00 a.m. Eastern Standard Time / 1:00 p.m. Central European Time to discuss the updated MICVO results following the late-breaking oral presentation at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium. To participate in the live webcast, participants may register in advance here. The event and accompanying slides can be accessed by visiting the investor relations section of the Company’s website at View Source An archived webcast will be available on the Company’s website following the event.

About Micvotabart Pelidotin (MICVO)
Micvotabart pelidotin (MICVO, formerly PYX-201) is an investigational antibody-drug conjugate (ADC) that uniquely targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extracellular matrix density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response.

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.

(Press release, Pyxis Oncology, NOV 18, 2026, View Source [SID1234674937])